{"id":785170,"date":"2023-09-20T09:47:34","date_gmt":"2023-09-20T13:47:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-2023-cantor-fitzgerald-global-healthcare-conference\/"},"modified":"2023-09-20T09:47:34","modified_gmt":"2023-09-20T13:47:34","slug":"newamsterdam-pharma-to-present-at-2023-cantor-fitzgerald-global-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-2023-cantor-fitzgerald-global-healthcare-conference\/","title":{"rendered":"NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">NAARDEN, The Netherlands and MIAMI, Sept.  20, 2023  (GLOBE NEWSWIRE) &#8212; NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or \u201cNewAmsterdam Pharma\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol (\u201cLDL-C\u201d), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Michael Davidson, M.D., chief executive officer of NewAmsterdam Pharma, will participate in a fireside chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2023 at 1:50 p.m. ET.<\/p>\n<p>A live webcast of the fireside chat will be available through the investor relations section of the NewAmsterdam Pharma website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=awZUntfhKeyXR44zCeQ-TdiCm4b5dGFlRzM91tWX4n3COw3Tflh60nCbwumoK4zwVSDavPfUfp-ThfxS11LBb4NhJUmj8WDQ43r9X2F47CdiG059kEBz7_LW3oq2QUUI\" rel=\"nofollow noopener\" target=\"_blank\">ir.newamsterdampharma.com<\/a>. Following the live webcast, an archived replay will be available on the Company\u2019s website.<\/p>\n<p>\n        <strong>About NewAmsterdam<\/strong>\n      <\/p>\n<p>Based in the Netherlands, NewAmsterdam (Nasdaq: NAMS) is a clinical-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been sufficiently adequate or well tolerated. We seek to fill a significant unmet need for a safe, cost-effective and convenient LDL-lowering therapy as an adjunct to statins, a class of lipid-lowering medications that are the current standard of care for high-risk CVD patients with high cholesterol. NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, as the preferred LDL-C lowering therapy to be used as an adjunct to maximally tolerated statin therapy for high-risk cardiovascular disease patients.<\/p>\n<p>\n        <strong>Company Contact<\/strong>\n      <\/p>\n<p>Matthew Philippe<br \/>P: 917-882-7512<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VLU5486sFwFvjpiNHOAPau8_Y6VnKW-9-E1TxQwMSvBnxxvzLuGTo9o1qE5XICu55kPTr691Vi0RBMuG-u5RO_0_m1OCdg21LPbJjiofiC1UaNVLBEcsaccPz-43AnwXXqKU6nOAGqnEmRJpHdZ3ZA==\" rel=\"nofollow noopener\" target=\"_blank\">matthew.philippe@newamsterdampharma.com<\/a><\/p>\n<p>\n        <strong>Media Contact<\/strong>\n      <\/p>\n<p>Spectrum Science on behalf of NewAmsterdam<br \/>Jenn Gordon<br \/>P: 1-202-957-7795<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uEfKfh_ZSqgMzJMVJAeD01WZ3RCaImehcJlRqtHIUpO2IccN6PMSkMrUAaskICT0k0-gItGETRVCiXQNpsar6Htgl5gOmXfYzAWmXEFl6207MoVsLKcnpQtCFfl0XLNS\" rel=\"nofollow noopener\" target=\"_blank\">jgordon@spectrumscience.com<\/a><\/p>\n<p>\n        <strong>Investor Contact<\/strong>\n      <\/p>\n<p>Stern Investor Relations on behalf of NewAmsterdam<br \/>Hannah Deresiewicz<br \/>P: 1 212-362-1200<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=D10wChoTm87rVr3FxY6LO69km47PT2n0EIFbnA47XyLbl2LdW37oeFZxaosfmIaPV1v9eQbUguiyLTuuvHS9fLF4rJGzxqlOsKYTbvcSybwkORlZpAAncw7fphPJD5dX\" rel=\"nofollow noopener\" target=\"_blank\">hannah.deresiewicz@sternir.com<\/a><\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNTEzNCM1ODIyOTY4IzIyNTAzNDE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MzI1MGE4NmQtZTg3Mi00YzczLWE1Y2ItZDhlMDNlODdhNDhiLTEyNjE4OTQ=\/tiny\/NewAmsterdam-Pharma-N-V.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NAARDEN, The Netherlands and MIAMI, Sept. 20, 2023 (GLOBE NEWSWIRE) &#8212; NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or \u201cNewAmsterdam Pharma\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol (\u201cLDL-C\u201d), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Michael Davidson, M.D., chief executive officer of NewAmsterdam Pharma, will participate in a fireside chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2023 at 1:50 p.m. ET. A live webcast of the fireside chat will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcast, an archived &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-2023-cantor-fitzgerald-global-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-785170","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-2023-cantor-fitzgerald-global-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NAARDEN, The Netherlands and MIAMI, Sept. 20, 2023 (GLOBE NEWSWIRE) &#8212; NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or \u201cNewAmsterdam Pharma\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol (\u201cLDL-C\u201d), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Michael Davidson, M.D., chief executive officer of NewAmsterdam Pharma, will participate in a fireside chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2023 at 1:50 p.m. ET. A live webcast of the fireside chat will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcast, an archived &hellip; Continue reading &quot;NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-2023-cantor-fitzgerald-global-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-20T13:47:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNTEzNCM1ODIyOTY4IzIyNTAzNDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-present-at-2023-cantor-fitzgerald-global-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-present-at-2023-cantor-fitzgerald-global-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference\",\"datePublished\":\"2023-09-20T13:47:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-present-at-2023-cantor-fitzgerald-global-healthcare-conference\\\/\"},\"wordCount\":290,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-present-at-2023-cantor-fitzgerald-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyNTEzNCM1ODIyOTY4IzIyNTAzNDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-present-at-2023-cantor-fitzgerald-global-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-present-at-2023-cantor-fitzgerald-global-healthcare-conference\\\/\",\"name\":\"NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-present-at-2023-cantor-fitzgerald-global-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-present-at-2023-cantor-fitzgerald-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyNTEzNCM1ODIyOTY4IzIyNTAzNDE=\",\"datePublished\":\"2023-09-20T13:47:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-present-at-2023-cantor-fitzgerald-global-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-present-at-2023-cantor-fitzgerald-global-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-present-at-2023-cantor-fitzgerald-global-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyNTEzNCM1ODIyOTY4IzIyNTAzNDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyNTEzNCM1ODIyOTY4IzIyNTAzNDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-present-at-2023-cantor-fitzgerald-global-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-2023-cantor-fitzgerald-global-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference - Market Newsdesk","og_description":"NAARDEN, The Netherlands and MIAMI, Sept. 20, 2023 (GLOBE NEWSWIRE) &#8212; NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or \u201cNewAmsterdam Pharma\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol (\u201cLDL-C\u201d), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Michael Davidson, M.D., chief executive officer of NewAmsterdam Pharma, will participate in a fireside chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2023 at 1:50 p.m. ET. A live webcast of the fireside chat will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcast, an archived &hellip; Continue reading \"NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-2023-cantor-fitzgerald-global-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-20T13:47:34+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNTEzNCM1ODIyOTY4IzIyNTAzNDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-2023-cantor-fitzgerald-global-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-2023-cantor-fitzgerald-global-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference","datePublished":"2023-09-20T13:47:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-2023-cantor-fitzgerald-global-healthcare-conference\/"},"wordCount":290,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-2023-cantor-fitzgerald-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNTEzNCM1ODIyOTY4IzIyNTAzNDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-2023-cantor-fitzgerald-global-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-2023-cantor-fitzgerald-global-healthcare-conference\/","name":"NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-2023-cantor-fitzgerald-global-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-2023-cantor-fitzgerald-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNTEzNCM1ODIyOTY4IzIyNTAzNDE=","datePublished":"2023-09-20T13:47:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-2023-cantor-fitzgerald-global-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-2023-cantor-fitzgerald-global-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-2023-cantor-fitzgerald-global-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNTEzNCM1ODIyOTY4IzIyNTAzNDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNTEzNCM1ODIyOTY4IzIyNTAzNDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-2023-cantor-fitzgerald-global-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/785170","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=785170"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/785170\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=785170"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=785170"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=785170"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}